MarketMoodz
DaVita Upgraded by Deutsche Bank, ~40% Upside Seen
Deutsche Bank has upgraded DaVita (DVA) to Buy from Hold and raised its price target to $220, signaling roughly 40% upside. The call follows DaVita’s Q1 beat, with revenue per treatment at $417.59 (up 4.4% YoY) and after-hours shares rising about 6% as investors greeted the results.
Key Takeaways
- Deutsche Bank upgrades DaVita to Buy and lifts the target to $220, implying ~40% upside.
- Q1 revenue per treatment was $417.59, up 4.4% year over year, with treatments growth just above consensus at 10 bps.
- Management guides 20–50 bps of annual demand growth for treatments; DB sees headwinds from SGLT2 inhibitors/GLP-1 impacts as not as severe.
- Shares moved about 6% higher in after-hours trading after the earnings beat, contributing to a ~38% YTD rise.
- There are 10 analysts covering DaVita, with 6 holding the stock; the note suggests upside relative to the current price.
People Involved
- Pito ChickeringDeutsche Bank Analyst
Entities Involved
- DaVita Inc. (DVA)Dialysis services provider
- Deutsche BankInvestment bank and research provider issuing the upgrade note
MarketMoodz Analysis
The upgrade provides a solid catalyst for DaVita, signaling renewed confidence in the company’s growth trajectory as dialysis demand appears to be on an uptick. The combination of higher revenue per treatment and solid treatment volumes underpins a potentially stronger top line and better pricing power, justifying the dividend of elevated valuation implied by a $220 price target.
From a historical perspective, Wall Street has emphasized the fragility of dialysis demand in the context of competitive therapies, but Deutsche Bank’s note argues headwinds are less severe than feared. The 10 bps beat on treatments and an expected 20–50 bps of annual demand growth align with a scenario where DaVita can sustain mid-single-digit revenue gains while navigating payer dynamics and competitive pressure.
What to watch next: monitor DaVita’s Q2 results for signs of durable volume growth and payer mix shifts, any changes to SGLT2/GLP-1 impact on starts, and whether more analysts raise targets as the stock approaches the newly elevated price target. The stock’s performance will hinge on execution, reimbursement trends, and the broader dialysis market dynamics.
Source: Original Article